To include your compound in the COVID-19 Resource Center, submit it here.

Ablynx's ozoralizumab meets RA endpoint

Ablynx N.V. (Euronext:ABLX) said ozoralizumab met the primary

Read the full 87 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE